FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319983237> ?p ?o ?g. }

• W4319983237 endingPage "53" @default.
• W4319983237 startingPage "53" @default.
• W4319983237 abstract "Background: In patients undergoing percutaneous coronary intervention (PCI), drug eluting stents (DES) are currently the standard of care. Stent design and alloy composition, biocompatibility of the drug-eluting polymer coating, the antiproliferative agent properties and release are the three main characteristics that affects DES performance. Cre8 (Alvimedica, Istanbul, Turkey) is a polymer-free amphilimus-eluting stents (PF-AES). In this study, we aimed to investigate the clinical efficacy and safety of Cre8 DES in daily cardiology practice. Methods: Patients presenting with chronic coronary syndrome (CCS) or acute coronary syndrome (ACS) including unstable angina pectoris (USAP), myocardial infarction with and without ST-segment elevation and treated with PCI using Cre8 DES between December 2015 and 2016 were retrospectively analyzed in this study. Results: Between December 2015 and 2016, 808 lesions of 664 patients treated with Cre8 DES in a single center were included in this retrospective analysis. The mean age of study group was 60 years (between 33 and 93 years) and were predominantly consisting of male patients (79.4%). The median follow-up duration was 487 days (min: 30 days, max: 919 days) and two-thirds of all patients presented with ACS. The culprit lesion was on left anterior descending artery (LAD) (40.5%) and right coronary artery (RCA) (25.9%) in most of the patients. The procedural success rate was 97.3%. Most of the lesions were type B1 (40.6%) according to American College of Cardiology/American Heart Association (ACC/AHA) coronary lesion classification. The device oriented primary end-point defined as target lesion failure (TLF) occurred in 52 (6.4%) of 808 lesions. The primary safety end-point was cardiac death in 20 patients (3.0%) and target vessel myocardial infarction in 2 patients (0.3%). Target vessel revascularization (TVR) occurred in 29 patients (4.4%) as primary safety endpoint. Multivariable logistic regression analysis revealed diabetes mellitus and ejection fraction as the predictors of mortality and device oriented primary end-point. Conclusions: This trial revealed clinical efficacy and safety of Cre8 stents in real world practice. Device oriented primary end points were similar with previous studies which are randomized, open label in nature and showed the efficacy and safety of Cre8 stent towards latest generation DES." @default.
• W4319983237 created "2023-02-11" @default.
• W4319983237 creator A5044577242 @default.
• W4319983237 creator A5058341833 @default.
• W4319983237 creator A5059697059 @default.
• W4319983237 creator A5084515173 @default.
• W4319983237 date "2023-02-06" @default.
• W4319983237 modified "2023-09-30" @default.
• W4319983237 title "Cre8 Drug Eluting Stent Performance in Daily Cardiology Practice" @default.
• W4319983237 doi "https://doi.org/10.31083/j.rcm2402053" @default.
• W4319983237 hasPublicationYear "2023" @default.
• W4319983237 type Work @default.
• W4319983237 citedByCount "0" @default.
• W4319983237 crossrefType "journal-article" @default.
• W4319983237 hasAuthorship W4319983237A5044577242 @default.
• W4319983237 hasAuthorship W4319983237A5058341833 @default.
• W4319983237 hasAuthorship W4319983237A5059697059 @default.
• W4319983237 hasAuthorship W4319983237A5084515173 @default.
• W4319983237 hasBestOaLocation W43199832371 @default.
• W4319983237 hasConcept C126322002 @default.
• W4319983237 hasConcept C164705383 @default.
• W4319983237 hasConcept C2777546689 @default.
• W4319983237 hasConcept C2777698277 @default.
• W4319983237 hasConcept C2777785093 @default.
• W4319983237 hasConcept C2778583881 @default.
• W4319983237 hasConcept C2778826181 @default.
• W4319983237 hasConcept C2780400711 @default.
• W4319983237 hasConcept C2780739214 @default.
• W4319983237 hasConcept C2781274984 @default.
• W4319983237 hasConcept C45393284 @default.
• W4319983237 hasConcept C500558357 @default.
• W4319983237 hasConcept C71924100 @default.
• W4319983237 hasConceptScore W4319983237C126322002 @default.
• W4319983237 hasConceptScore W4319983237C164705383 @default.
• W4319983237 hasConceptScore W4319983237C2777546689 @default.
• W4319983237 hasConceptScore W4319983237C2777698277 @default.
• W4319983237 hasConceptScore W4319983237C2777785093 @default.
• W4319983237 hasConceptScore W4319983237C2778583881 @default.
• W4319983237 hasConceptScore W4319983237C2778826181 @default.
• W4319983237 hasConceptScore W4319983237C2780400711 @default.
• W4319983237 hasConceptScore W4319983237C2780739214 @default.
• W4319983237 hasConceptScore W4319983237C2781274984 @default.
• W4319983237 hasConceptScore W4319983237C45393284 @default.
• W4319983237 hasConceptScore W4319983237C500558357 @default.
• W4319983237 hasConceptScore W4319983237C71924100 @default.
• W4319983237 hasIssue "2" @default.
• W4319983237 hasLocation W43199832371 @default.
• W4319983237 hasOpenAccess W4319983237 @default.
• W4319983237 hasPrimaryLocation W43199832371 @default.
• W4319983237 hasRelatedWork W193640619 @default.
• W4319983237 hasRelatedWork W2129387994 @default.
• W4319983237 hasRelatedWork W2313109464 @default.
• W4319983237 hasRelatedWork W2369288055 @default.
• W4319983237 hasRelatedWork W2372758922 @default.
• W4319983237 hasRelatedWork W249904011 @default.
• W4319983237 hasRelatedWork W2822274293 @default.
• W4319983237 hasRelatedWork W2894290188 @default.
• W4319983237 hasRelatedWork W2920352240 @default.
• W4319983237 hasRelatedWork W2966011017 @default.
• W4319983237 hasVolume "24" @default.
• W4319983237 isParatext "false" @default.
• W4319983237 isRetracted "false" @default.
• W4319983237 workType "article" @default.